WuXi Biologics Received First Manufacturing License from Japan and Completed 12 Global Regulatory Inspections in 2021 Year to Date

WuXi Biologics Received First Manufacturing License from Japan and Completed 12 Global Regulatory Inspections in 2021 Year to Date

WuXi Biologics (2269.HK, WuXi Bio), a global company with leading open-access biologics technology platforms, offering end-to-end solutions for discovery, development and manufacturing, announced that it received the Manufacturing Licence from Japan’s Minister of Health, Labor and Welfare (MHLW) for its drug substance facility (MFG2) at Wuxi city, China. After 2 days of remote GMP inspection, no issues were spotted, and WuXi Biologics was given the license. MFG2 will be commencing with the commercial manufacturing of a COVID-19 neutralising antibody for one of its global partners. So far, WuXi Biologics has completed nearly 20 regulatory inspections conducted by 7 different agencies including U.S. FDA, EMA, NMPA.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company’s history and achievements demonstrate its commitment to providing a truly ONE-stop service offering and strong value proposition to its global clients.

The company is currently conducting on behalf of its clients and partners (as of June 30, 2021) a total of 408 integrated projects, including 212 in pre-clinical development stage, 160 in early-phase (phase I and II) clinical development, 32 in late-phase (phase III) development and 4 in commercial manufacturing. With a total estimated capacity of exceeding 430,000 litres for biopharmaceutical production planned after 2024 in China, Ireland, the U.S., Germany, and Singapore, WuXi Biologics will provide its biomanufacturing partners with a robust and premier-quality global supply chain network.

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of its ethos and business strategy and aims to become a global ESG leader in biologics manufacturing. We use next-generation clean biomanufacturing technologies and utilize cleaner energy sources. We have also established an ESG committee led by the CEO to increase efficiency while advancing commitment to sustainability. For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

NEWS PROVIDED BY
WuXi Biologics
 Sep 01, 2021, 02:00 ET
View Original Content

WuXi Biologics (2269.HK, WuXi Bio), a global company with leading open-access biologics technology platforms, offering end-to-end solutions for discovery, development and manufacturing, announced that it received the Manufacturing Licence from Japan’s Minister of Health, Labor and Welfare (MHLW) for its drug substance facility (MFG2) at Wuxi city, China. After 2 days of remote GMP inspection, no issues were spotted, and WuXi Biologics was given the license. MFG2 will be commencing with the commercial manufacturing of a COVID-19 neutralising antibody for one of its global partners. So far, WuXi Biologics has completed nearly 20 regulatory inspections conducted by 7 different agencies including U.S. FDA, EMA, NMPA.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company’s history and achievements demonstrate its commitment to providing a truly ONE-stop service offering and strong value proposition to its global clients.

The company is currently conducting on behalf of its clients and partners (as of June 30, 2021) a total of 408 integrated projects, including 212 in pre-clinical development stage, 160 in early-phase (phase I and II) clinical development, 32 in late-phase (phase III) development and 4 in commercial manufacturing. With a total estimated capacity of exceeding 430,000 litres for biopharmaceutical production planned after 2024 in China, Ireland, the U.S., Germany, and Singapore, WuXi Biologics will provide its biomanufacturing partners with a robust and premier-quality global supply chain network.

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of its ethos and business strategy and aims to become a global ESG leader in biologics manufacturing. We use next-generation clean biomanufacturing technologies and utilize cleaner energy sources. We have also established an ESG committee led by the CEO to increase efficiency while advancing commitment to sustainability. For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

NEWS PROVIDED BY
WuXi Biologics
 Sep 01, 2021, 02:00 ET
View Original Content

WuXi Biologics (2269.HK, WuXi Bio), a global company with leading open-access biologics technology platforms, offering end-to-end solutions for discovery, development and manufacturing, announced that it received the Manufacturing Licence from Japan’s Minister of Health, Labor and Welfare (MHLW) for its drug substance facility (MFG2) at Wuxi city, China. After 2 days of remote GMP inspection, no issues were spotted, and WuXi Biologics was given the license. MFG2 will be commencing with the commercial manufacturing of a COVID-19 neutralising antibody for one of its global partners. So far, WuXi Biologics has completed nearly 20 regulatory inspections conducted by 7 different agencies including U.S. FDA, EMA, NMPA.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company’s history and achievements demonstrate its commitment to providing a truly ONE-stop service offering and strong value proposition to its global clients.

The company is currently conducting on behalf of its clients and partners (as of June 30, 2021) a total of 408 integrated projects, including 212 in pre-clinical development stage, 160 in early-phase (phase I and II) clinical development, 32 in late-phase (phase III) development and 4 in commercial manufacturing. With a total estimated capacity of exceeding 430,000 litres for biopharmaceutical production planned after 2024 in China, Ireland, the U.S., Germany, and Singapore, WuXi Biologics will provide its biomanufacturing partners with a robust and premier-quality global supply chain network.

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of its ethos and business strategy and aims to become a global ESG leader in biologics manufacturing. We use next-generation clean biomanufacturing technologies and utilize cleaner energy sources. We have also established an ESG committee led by the CEO to increase efficiency while advancing commitment to sustainability. For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

NEWS PROVIDED BY
WuXi Biologics
 Sep 01, 2021, 02:00 ET
View Original Content

WuXi Biologics (2269.HK, WuXi Bio), a global company with leading open-access biologics technology platforms, offering end-to-end solutions for discovery, development and manufacturing, announced that it received the Manufacturing Licence from Japan’s Minister of Health, Labor and Welfare (MHLW) for its drug substance facility (MFG2) at Wuxi city, China. After 2 days of remote GMP inspection, no issues were spotted, and WuXi Biologics was given the license. MFG2 will be commencing with the commercial manufacturing of a COVID-19 neutralising antibody for one of its global partners. So far, WuXi Biologics has completed nearly 20 regulatory inspections conducted by 7 different agencies including U.S. FDA, EMA, NMPA.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company’s history and achievements demonstrate its commitment to providing a truly ONE-stop service offering and strong value proposition to its global clients.

The company is currently conducting on behalf of its clients and partners (as of June 30, 2021) a total of 408 integrated projects, including 212 in pre-clinical development stage, 160 in early-phase (phase I and II) clinical development, 32 in late-phase (phase III) development and 4 in commercial manufacturing. With a total estimated capacity of exceeding 430,000 litres for biopharmaceutical production planned after 2024 in China, Ireland, the U.S., Germany, and Singapore, WuXi Biologics will provide its biomanufacturing partners with a robust and premier-quality global supply chain network.

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of its ethos and business strategy and aims to become a global ESG leader in biologics manufacturing. We use next-generation clean biomanufacturing technologies and utilize cleaner energy sources. We have also established an ESG committee led by the CEO to increase efficiency while advancing commitment to sustainability. For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

NEWS PROVIDED BY
WuXi Biologics
 Sep 01, 2021, 02:00 ET
View Original Content

Comments

Leave A Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

bag